Interstitial lung diseases (ILD) encompass a diverse group of pulmonary conditions characterized by inflammation and fibrosis of the lung interstitium. This article provides a comprehensive overview of ILD, focusing on its etiology, classification, clinical presentation, diagnosis, and management.
ILDs can be idiopathic or secondary to various factors such as occupational exposure, drugs, and systemic diseases. Based on etiology, ILDs are classified into idiopathic interstitial pneumonias, connective tissue disease-associated ILD, and occupational ILD, among others.
Patients with ILD typically present with progressive dyspnea and non-productive cough. Physical examination may reveal inspiratory crackles and finger clubbing. Hypoxemia and restrictive pattern are common findings on arterial blood gas analysis and pulmonary function tests respectively.
High-resolution computed tomography (HRCT) is the imaging modality of choice for ILD. It helps in identifying the pattern of disease which can be either usual interstitial pneumonia (UIP) or non-specific interstitial pneumonia (NSIP). Bronchoalveolar lavage and lung biopsy may be required in certain cases for definitive diagnosis.
Management of ILD is largely based on the underlying cause. In idiopathic cases, treatment is primarily supportive, including oxygen therapy and pulmonary rehabilitation. Immunosuppressive therapy may be used in cases associated with connective tissue diseases. Lung transplantation may be considered in advanced cases.
In conclusion, ILD represents a complex group of lung disorders with diverse etiology and clinical presentation. High clinical suspicion, coupled with appropriate diagnostic modalities, is key to timely diagnosis and management. As healthcare professionals, understanding the nuances of ILD is crucial for providing optimal patient care.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation